The enzyme soluble epoxide hydrolase (sEH; EC 3.3.2.10) is emerging as a pharmacological target, as its inhibition has been shown to have beneficial effects in metabolic disorders [21] and in neurodegenerative diseases, such as Alzheimer’s disease (AD) [22,23] and Parkinson’s disease (PD) [24]. Here, EPHX2 is linked to early-onset autosomal dominant Alzheimer disease.